High immunoproteasome and low constitutive proteasome subunit levels correlate with sensitivity to bortezomib-containing chemotherapy: update from the Children’s Oncology Group AALL1231 trial

Study ID Citation

Roeten MSF, Van Meerloo J, Van Dijk SN, Kwidama Z, Jenkins G, Teachey DT, Devidas M, Loh ML, Kaspers GJL, Zweegman S, Jansen G, Horton TM, Cloos J. High immunoproteasome and low constitutive proteasome subunit levels correlate with sensitivity to bortezomib-containing chemotherapy: update from the Children’s Oncology Group AALL1231 trial. Haematologica. 2025 Jun 1;110(6):1379-1383. doi: 10.3324/haematol.2024.286171. Epub 2025 Jan 30. PMID: 39882653; PMCID: PMC12130773.

Abstract

No abstract provided.

Link To Publication opens in a new tab